NeuroSense Therapeutics (NRSN) Company Report

Analyst Coverage

Research analysts covering NeuroSense Therapeutics.

Recent press releases and 8-K filings for NRSN.

NRSN Receives FDA Clearance for Phase 3 ALS Trial

NRSN

New Projects/Investments

NeuroSense Therapeutics received FDA clearance to initiate a pivotal Phase 3 clinical trial for its lead drug candidate, PrimeC, for the treatment of amyotrophic lateral sclerosis (ALS).
The global pivotal Phase 3 trial, named PARAGON, is powered at over 95% to achieve its primary endpoint and will expand upon promising results from the Phase 2b PARADIGM trial.
The company is preparing for trial initiation and aims to enroll its first patient in the coming months upon securing strategic resources.
The PARAGON trial is expected to be conducted in the U.S. and EU, involving 300 ALS patients in a 12-month placebo-controlled study with an open-label extension.
Additional details regarding the PARAGON trial design and timelines will be provided in an investor webinar on December 8th, 2025.

Nov 24, 2025, 2:56 PM

NeuroSense Therapeutics Ltd. Schedules Special Shareholder Meeting for Equity Compensation Approvals

NRSN

Executive Compensation

Proxy Vote Outcomes

NeuroSense Therapeutics Ltd. will hold a Special Meeting of Shareholders on December 30, 2025, to vote on proposals concerning equity compensation for its non-management directors and Chief Executive Officer.
The company proposes to grant 315,000 restricted shares to non-management directors for their 2024 service.
An additional 476,435 restricted shares are proposed for non-management directors as equity compensation in lieu of deferred cash fees, due to the company's limited cash resources.
CEO Alon Ben-Noon is proposed to receive 360,777 restricted shares in lieu of approximately $930,150 in unpaid cash bonuses for 2022, 2023, and 2024, and to adjust for the increase in ordinary shares.

Nov 21, 2025, 11:36 AM

NeuroSense Therapeutics Reports Positive Alzheimer's Biomarker Findings for PrimeC

NRSN

New Projects/Investments

On October 6, 2025, NeuroSense Therapeutics Ltd. announced that its drug candidate, PrimeC, demonstrated statistically significant reductions in multiple Alzheimer's disease (AD) biomarkers.
These positive findings were derived from plasma samples collected during the company's Phase-2b PARADIGM study.
PrimeC treatment significantly reduced several AD-associated microRNAs, including miR-146a-5p, miR-21-5p, miR-let-7a-5p, and miR-let-7e-5p, which are implicated in neuroinflammation and neurodegenerative activity.
The company views these results as supporting PrimeC's potential as a disease-modifying therapy for AD by targeting central biological pathways.
NeuroSense plans to use these biomarker data to guide the design of a follow-on AD study, while also advancing PrimeC's Phase 3 readiness program for ALS.

Oct 6, 2025, 1:06 PM

Halberd Corporation Acquires NeuroSense AI Corp.

NRSN

M&A

New Projects/Investments

Product Launch

Halberd Corporation (OTC: HALB) has acquired NeuroSense AI Corp., which is now an 89%-owned subsidiary.
NeuroSense AI is a groundbreaking artificial intelligence platform designed to revolutionize behavioral analysis for traumatic brain injury (TBI) research and clinical assessment, utilizing multi-modal behavioral signal fusion powered by Claude AI technology.
The platform aims to provide a first-mover advantage in the rapidly growing $240 billion by 2030 global behavioral health market, with immediate applications in research, clinical settings, pharmaceutical development, and government/military.
Halberd plans to implement this capability into upcoming Phase 2 animal testing at Mississippi State University and intends to pursue FDA regulatory pathways for the platform.

Sep 29, 2025, 12:00 PM

NeuroSense Therapeutics Ltd. Announces Positive PrimeC ALS Study Data Analysis

NRSN

New Projects/Investments

NeuroSense Therapeutics Ltd. announced a new analysis of 18-month data from its Phase 2b PARADIGM study of PrimeC in ALS.
The analysis demonstrated a statistically significant effect at 18 months (p=0.03), reflected in a 28% relative difference in ALS Functional Rating Scale-Revised (ALSFRS-R) decline favoring patients who received PrimeC from the study's beginning.
These results reinforce PrimeC’s potential as a disease-modifying therapy for ALS.

Sep 2, 2025, 12:36 PM

Get instant answers from SEC filings, earnings calls & more